| Literature DB >> 32507334 |
Alejandro Macias1, Guillermo Ruiz-Palacios2, Jose Ramos-Castaneda3.
Abstract
Developing a completely effective and safe dengue vaccine has been a complicated process. Dengvaxia®, by Sanofi-Pasteur, and recently TAK003, by Takeda, have strengths and weaknesses, but they seem to complement each other. In this work, we elaborate a rationale that could be applicable in a combined program of these vaccines for the control of dengue.Keywords: Dengue; Public health; Vaccination program; Vaccine
Mesh：
Substances：
Year: 2020 PMID： 32507334 DOI： 10.1016/j.vaccine.2020.05.088
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641